PPD: Meeting biopharma demand is a ‘substantial undertaking’ for CRO industry

This content item was originally published on www.outsourcing-pharma.com, a William Reed online publication.

By Melissa Fassbender contact

- Last updated on GMT

PPD Laboratories SVP says its been a substantial undertaking – for every company in the CRO industry – to meet the demand for biopharmaceuticals as the industry's pipeline continues to expand.

“I think it’s no secret within the industry that one of the fastest growing areas of demand for pharmaceutical companies has been their development needs for biopharmaceuticals,” ​said Jon F. Denissen, PhD, senior vice president, PPD Laboratories, at the company’s recently expanded facility in Middleton, WI.

To meet this demand, the contract research organization (CRO) has been expanding capacity globally. Most recently, PPD opened a 32,000 square-foot analytical laboratory, making room for more than 100 new employees.

“It’s been a substantial undertaking I think for every company in the CRO industry to keep up with demand for biopharmaceuticals,”​ Denissen told us after touring the new laboratory.

For a look inside the lab, and to hear more from Denissen on how the company is working to keep up with demand, catch our quick video above.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars